Clinical Trials Browser

Phase 1/2 × Leflunomide × 30 days × Clear all

NCT03709446 2026-03-19

Leflunomide in Previously Treated Metastatic Triple Negative Cancers

Phase 1/2 Completed

Breast Diseases, Breast Neoplasms, Triple Negative Breast Neoplasms